Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02183493
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: Low dose ASADrug: High dose ASADrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1889
- Registration Number
- NCT02183688
Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Merck Glucophage® high doseDrug: Merck Glucophage® low doseDrug: BMS Glucophage® high doseDrug: BMS Glucophage® low dose
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02183571
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 1356 BS - single rising doseDrug: BI 1356 BS - multiple rising doseDrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02183311
Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia
Phase 3
Terminated
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: Eschscholtzia CalifornicaDrug: Eschscholtzia Californica Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 49
- Registration Number
- NCT02183233
Bioequivalence Study of UH-AC 62 XX Tablets Compared With the Capsule Formulations in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: UH-AC 62 XX tabletDrug: UH-AC 62 XX capsule
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT02181907
Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02183428
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 1356 BS - intravenousDrug: PlaceboDrug: BI 1356 BS - Tablet
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02183298
Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02183077
Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar
Phase 2
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 381
- Registration Number
- NCT02183051